|
 |
AmBisomeThis page contains recent news articles, when available, and an overview of AmBisome but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.Gilead said quarterly sales for Letairis, a pulmonary arterial hypertension treatment, surged 52% to $48.1 million and sales of AmBisome liposome for ... Trading Markets (press release) SanDisk Announces Third Quarter 2009 Financial Results - Oct 20, 2009 1644407 1188497 Total Antiviral products - Other International 82066 72053 239645 209389 1470231 1231533 4221278 3399597 AmBisome 77064 72884 214645 ... Reuters GileadSciencesgibtRekord-Finanzergebnis für das dritteQuartal2009bekannt - Oct 23, 2009 Truvada, Viread, Hepsera, AmBisome, Letairis, Ranexa und Cayston sind eingetragene Marken von Gilead Sciences, Inc. Atripla ist eine eingetragene Marke von ... Reuters GileadSciencesannonce des résultats financiers record pour le troisième ... - Oct 23, 2009 Truvada, Viread, Emtriva, Hepsera, AmBisome, Letairis, Ranexa et Cayston sont des marques déposées de Gilead Sciences, Inc. Atripla est une marque déposée ... Reuters BUSINESS WIRE: Gilead Sciences gibt Rekord-Finanzergebnis für das dritte ... - Oct 23, 2009 82.066 72.053 239.645 209.389 international 1.470.231 1.231.533 4.221.278 3.399.597 AmBisome 77.064 72.884 214.645 213.680 Letairis 48.073 31.656 ... Vereinigte Wirtschaftsdienste GILD,European CHMP Adopts Positive Opinion for Aztreonam - Jun 26, 2009 ...an oral formulation for the treatment of chronic hepatitis B; AmBisome, amphotericin B liposome injection to treat serious invasive fungal infections; TransWorldNews (press release) Cancer deaths and near-misses prompted drug safety review - Mar 6, 2009 The drug comes in four formulations, Abelcet, Fungizone, AmBisome and Amphocil, and recommended dosage ranges from 1 to 5mg/kg. The patient safety agency Times Online Gilead Sciences relies on CV Therapeutics, other deals to expand - Mar 13, 2009 A year later, the FDA approved Gilead's AmBisome, for life-threatening fungal infections. And in 1999, the FDA also approved Gilead's Tamiflu, which Gilead San Jose Mercury News UN: Press Conference on Maternal Girls’ Health, Neglected Tropical ... - Feb 25, 2009 The most effective treatment for kala azar -– Ambisome -- was too expensive for most health ministries. For example, it was 0 per patient in Bihar, India, ISRIA (subscription) Simple new test for kala azar - Feb 22, 2009 It is also expensive, costing at least $100 in private pharmacies. The second line treatment, which is used when SSG fails, is called ambisome. East African Gilead Roasts Fourth-Quarter Targets - Jan 27, 2009 The company also reported worldwide revenue of $76.4 million from Hepsera, $75.9 million from Ambisome and $36.1 million for Letairis. TheStreet.com Gilead Sciences Announces Record Fourth Quarter and Full Year 2008 ... - Jan 28, 2009 Sales of AmBisome® (amphotericin B) liposome for injection for severe fungal infections increased 12 percent to $76.0 million for the fourth quarter of 2008 Lifescience-online, Gilead Sciences annonce des résultats financiers record pour le ... - Jan 29, 2009 Les ventes de liposome AmBisome ® (amphotéricine B) pour injection contre les infections fongiques graves ont augmenté de 12 % pour atteindre les 76,0 Boursier.com (Communiqué de presse), *vwd/BUSINESS WIRE: Gilead Sciences gibt Rekord-Finanzergebnisse ... - Jan 30, 2009 AmBisome Der Umsatz mit dem AmBisome^®-(Amphotericin B)-Liposom zur Injektion bei schwerwiegenden Pilzinfektionen erhöhte sich um 12 Prozent auf USD 76,0 ddp-direkt.de (press release), *vwd/BUSINESS WIRE: Gilead Sciences gibt Rekord-Finanzergebnisse ... - Jan 30, 2009 ...international 1.272.835 941.083 4.672.432 3.439.994 AmBisome 75.971 67.807 289.651 262.571 Letairis 36.176 14.754 112.855 21.020 Sonstige Produkte 2.790 Vereinigte Wirtschaftsdienste, Journal de Pharmacie Clinique - Oct 30, 2008 La plupart de ces molécules (Ambisome ® , Cancidas ® , Vfend ® ) font partie des médicaments remboursés en sus du coût des groupes homogènes de séjour (GHS) Journal Pharmacie Clinique (Abonnement), Médicos sin Fronteras refuerza la innovación en enfermedades olvidadas - Oct 29, 2008 MSF ha optado por un fármaco un poco más caro pero mucho más efectivo: la anfotericina B liposomal (de nombre comercial AmBisome®, producido por Gilead), Xornal, Gilead Sciences Announces Third Quarter 2008 Financial Results - Oct 16, 2008 Sales of AmBisome(R) (amphotericin B) liposome for injection for severe fungal infections increased six percent to $72.9 million for the third quarter of Centre Daily Times, Gilead Sciences annonce ses résultats financiers pour le troisième ... - Oct 19, 2008 Les ventes du liposome AmBisome ® (amphotéricine B) pour injection pour le traitement d'infections fongiques graves ont augmenté de six pour cent à 72,9 Fininfo (Communiqués de presse), *vwd/BUSINESS WIRE: Gilead Sciences gibt die Finanzergebnisse des ... - Oct 19, 2008 AmBisome Die Produktverkäufe von AmBisome^ ®-(Amphotericin B)-Liposom zur Injektion für schwerwiegende Pilzinfektionen erreichten im dritten Quartal 2008 ddp-direkt.de, Gilead Q3 Profit Up On Higher Sales Of AIDS Drug; Tops Street Estimate - Oct 16, 2008 Sales of AmBisome, an injection for severe fungal infections, advanced 6% to $72.9 million from the same quarter last year Royalty, contract and other Trading Markets (press release), Médicos Sin Fronteras refuerza la innovación médica en ... - Oct 1, 2008 MSF ha optado por un fármaco un poco más caro pero mucho más efectivo: la anfotericina B liposomal (de nombre comercial AmBisome*, producido por Gilead), Europa Press - Diario Social, “Las enfermedades olvidadas matan miles de personas cada día en ... - Oct 3, 2008 MSF comenzó a administrar un fármaco un poco más caro, pero mucho más efectivo: AmBisome®, producido por Gilead, cuyo tratamiento sólo dura 10 días, Guadalajara Dos Mil, Gilead may shoot past big firms' buyout hunts Sep 2, 2008 ...it gained a sales organization and the revenue stream that came with NeXstar's drug AmBisome, a treatment for serious fungal infections.San Francisco Chronicle, FDA Approvals: Viread and Cancidas Aug 21, 2008 ...after a 70-mg/m 2 loading dose on day 1) or 3 mg/kg IV daily of liposomal amphotericin B (AmBisome; Gilead Sciences, Inc, for Fujisawa Healthcare, Inc).Medscape (subscription) More dead than alive - surviving kala azar - Jul 24, 2008 MSF in Bihar is therefore using a newer drug, liposomal amphoterycin B, marketed under the brand name Ambisome.. "This is a very good drug. Medecins Sans Frontieres, Zoek in het archief - Jul 17, 2008 AmBisome For the second quarter of 2008, sales of AmBisome(R) (amphotericin B) liposome for injection for severe fungal infections were $69.8 million, Netherlands Corporate News (persbericht), Gilead Sciences, Inc. Q2 2008 Earnings Call Transcript - Jul 31, 2008 Sales of AmBisome for severe fungal infections were $70 million for the second quarter of 2008, a year-over-year increase of 8%, primarily driven by a Seeking Alpha, Earnings Preview: Gilead Sciences - Jul 16, 2008 Other non-HIV drugs already owned by Gilead include the hepatitis B treatment Hepsera and the fungal infection treatment AmBisome. BY THE NUMBERS: Analysts Forbes, *vwd/BUSINESS WIRE: Gilead Sciences gibt die Finanzergebnisse des ... - Jul 21, 2008 AmBisome Die Produktverkäufe von AmBisome^ ®-(Amphotericin B)-Liposom zur Injektion für schwerwiegende Pilzinfektionen erreichten im zweiten Quartal 2008 ddp-direkt.de, Gilead Sciences annonce ses résultats financiers pour le second ... - Jul 21, 2008 Pour le second trimestre 2008, la vente du liposome AmBisome ® (amphotéricine B) pour injection pour le traitement d’infections fongiques graves, Business Wire (press release), Polytherics Complex technology to make drug solubility simple - 02 Jun 2008 An unmodified liposomal formulation of amphotericin B, Gilead Sciences' AmbiSome, has been approved for treating leishmaniasis and other severe infections In-PharmaTechnologist.com, Gilead Sciences Announces First Quarter 2008 Financial Results - Apr 16, 2008 Sales of AmBisome(R) (amphotericin B) liposome for injection for the first quarter of 2008 were $71.0 million, an increase of 15 percent from $61.5 million Centre Daily Times, HIV drug sales push Gilead Sciences Q1 profit higher - Apr 16, 2008 ...saw sales increase 16 percent to $83 million, while quarterly sales of the severe fungal infection treatment AmBisome rose 15 percent to $71 million. Bizjournals.com, HIV Drug Sales Boost Gilead Profits - Apr 16, 2008 And the company reported $71 million from AmBisome for severe fungal infections, also beating the $67 million consensus target. Sales benefitted from the TheStreet.com Gilead Sciences' HIV drug sales push 1Q profit higher - Apr 16, 2008 The company's hepatitis B treatment Hepsera had sales of $83 million, a 16 percent increase, while sales of the severe fungal infection treatment AmBisome Forbes, Gilead Sciences, Inc. Q1 2008 Earnings Call Transcript - Apr 16, 2008 Sales of AmBisome were $71 million for the first quarter of 2008, an increase of 15% when compared to the first quarter of 2007, of which approximately 8% Seeking Alpha, Friday's Health Winners & Losers - Apr 11, 2008 ...as well as $79 million from Hepsera, $67 million in sales of antifungal AmBisome and $25 million from the hypertension drug Letairis. TheStreet.com Gilead Sciences Q1 Profit Rises On HIV Drug Sales - Update [GILD] - Apr 16, 2008 Fungus infection treatment AmBisome reported sales increase of 15% to $71 million. Royalty, contract and other revenues, primarily from collaborations with RTT News, AEterna Zentaris and Paladin Labs Complete Sale and Purchase of ... - Apr 1, 2008 Other currently available treatments are liposomal amphotericin (Ambisome®) and Paromomycin. Leishmaniasis is an infectious disease transmitted by the bite CNNMoney.com AEZ: Sale of Miltefosine to Paladin Labs for C$9.125M - Mar 3, 2008 Other current available treatments are liposomal amphotericin (Ambisome(R)) and Paromomycin. KNOBIAS DISCLAIMER: All statements made in this article were Trading Markets (press release), New nanocarriers for cancer treatment - Mar 2, 2008 In fact, the FDA-approved drugs Ambisome, Doxil and DaunoXome all contain liposomal formulations. Such liposomes are typically comprised of glycerol-based Nanowerk LLC, AEterna Zentaris and Paladin Labs Announce Sale and Purchase of ... - Mar 3, 2008 Other current available treatments are liposomal amphotericin (Ambisome®) and Paromomycin. Leishmaniasis is an infectious disease transmitted by the bite of CNNMoney.com |
|
Health Home | Conditions | Cancer | Medications | Surgery | Vaccines The Cancer News Network
COPYRIGHT 2009 CANCERNEWSNETWORK | Privacy |
